The relationship of CD34 expression or BRAFV600E mutation in GG with tumor survival (PFS or overall survival) have been studied, previously (Chappé et al., 2013; Dahiya et al., 2013; Chen et al., 2017; Zaky et al., 2018; Lisievici et al., 2021). Here, CD34 is linked to neoplasm.